(AOF) – Genomic Vision, a biotechnology company, announces the expansion of its RCA services, highlighting its continued commitment to growing its service offerings for oncology and drug discovery. Going beyond standard RCA offerings, Genomic Vision brings tailor-made solutions and can now provide its customers with new replication parameters such as fork speed, analog ratio, fork symmetry, fork dropout. forking and triggering a new origin.
Genomic Vision also offers a new Locus-RCA service, attracting growing interest in the scientific community. Locus-RCA allows assessment of changes in replication dynamics in a specific region of the genome, such as oncogenes and tumor suppressor genes.
Genomic Vision (GV) provides tailored RCA services to meet specific needs, demonstrating its commitment to providing personalized genomic solutions to its partners to advance the pharmaceutical and biotechnology industries.
Genomic Vision’s Research and Development team is actively conducting new experiments to offer an even wider range of parameters and biomarkers for analysis within the RCA, continually developing the information provided to its customers.
© AOF Legal notice
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, rebroadcast, translation, commercial exploitation or not, creation of a hypertext link or reuse in any manner whatsoever of this information is subject to the prior written agreement of OPTION FINANCE SAS and its contributors. AOF can be reached at the following address aof@optionfinance.fr OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to gross negligence, OPTION FINANCES SAS and its contributors do not in any way guarantee the absence of errors and defects, even hidden ones, nor the exhaustive nature or lack of conformity for any use of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for delays or interruptions which could affect access to the latter. The user of the OPTION FINANCE SAS service will use AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news Every morning, the information to remember on the financial markets.
2023-11-02 10:35:12
#Genomic #Vision #expands #Replication #Combing #Assay #service #offering
